- Exclusive content—including recommendations about how to incorporate FINACEA treatment into your daily routine.
- Dermatologist-recommended products—to help make the most of your FINACEA treatment.
- Special savings—save up to $30 on FINACEA in downloadable coupons and up to $10 on rosacea friendly skin-care products.
Enroll in Skin Savvy now
If your dermatologist has prescribed FINACEA and you'd like to have access to this exclusive content, please click below.
Intendis values your privacy and the confidentiality of your personal information. By submitting the information below, I give Intendis (and those agents working on its behalf) permission to: 1) Provide me with materials about rosacea and dermatology. 2) Contact me about dermatology-related health topics. 3) Use my information to help develop new products, services, and programs relating to dermatology. I can revoke this authorization at any time by mailing or faxing a written request to Intendis, Inc., PO Box 1000, Pine Brook, NJ 07058, Fax: 973-487-2478. This authorization expires three (3) years after the last communication between me and Intendis. Intendis will use your information only to provide you with materials and information relating to rosacea.
Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.
Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.
Images are for illustrative purposes only.